Shares of atai Life Sciences (NASDAQ:ATAI) traded higher in the premarket on Tuesday after the company and its partner, ...

An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...

For patients seeking substance use treatment, an integrated approach focusing on mental health first paves the way for ...

Her relapse into depression felt like defeat—but it offered vital clues to achieving lasting psychiatric relief. The 67-year-old woman from Alabama had already endured four major depressive episodes ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

The psilocybin found in "magic mushrooms" might be key to quelling depression among people battling cancer, a new study found ...

Psychedelics research gains support from the Trump administration for treating PTSD and mental health conditions, with Veterans Affairs exploring treatments that show promise in clinical trials.

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most Read from BloombergBezos Wedding Draws Protests, Soul ...